Thoracic Malignancy
Conditions
Interventions
Conversion from oral oxycodone to application of 3-day fentanyl matrix patch for consective 15 days
Sponsors
Department of Respiratory Medicine, Osaka University Hospital
Department of Respiratory Medicine, Osaka Police Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) confirmed diagnosis of thoracic malignancy 2) age > 20 years 3) persistent mlignancy-related pain refractory to non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen 4) numeric rating scale (NRS) for pain under 3 for at least two consecutive days by low dose (20 mg/day or less) of oral oxycodone (Oxycontine, Shionogi-Pherma, Japan) 5) Written informed consent
Exclusion criteria
Exclusion criteria: 1) prior history of allergy or hypersensitivity to opioids 2) prior history of opioid abuse 3) clinically significant cardiac, renal or hepatic insufficiency 4) increased intracranial pressure or impaired cognitive function 5) active and extensive skin disease precluding application of the transdermal delivery system 6) persistent fever of 40 degrees Celsius or over 7) pregnancy, lactation and suspicion of being pregnant 8) prior use of any opioid-antagonists within 2 days before switching to fentanyl patch.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| patients' global assessment scores | — |
Secondary
| Measure | Time frame |
|---|---|
| pain intensity, adverse effects and use of rescue oxycodone | — |
Countries
Japan
Contacts
Public ContactTakashi Kijima
Osaka University Hospital Department of Respiratory Medicine
Outcome results
None listed